US · GERN
Geron Corporation
- Sector
- Healthcare · Biotechnology
- Headquarters
- Foster City, CA 94404
- Website
- geron.com
Price · as of 2024-12-31
$1.58
Market cap 1.07B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $4,942.88 | +312,740.51% |
| Intrinsic Value(DCF) | $0.77 | -51.27% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $4.57 | $36.27 | $0.70 | $0.00 | $0.00 |
| 2011 | $1.74 | $26.23 | $0.29 | $0.00 | $17.19 |
| 2012 | $1.39 | $25.34 | $0.13 | $0.00 | $0.00 |
| 2013 | $4.28 | $30.25 | $0.15 | $0.00 | $12.65 |
| 2014 | $4.34 | $29.98 | $0.61 | $0.00 | $0.38 |
| 2015 | $2.80 | $477.48 | $35.96 | $0.90 | $0.85 |
| 2016 | $2.11 | $527.23 | $0.57 | $0.00 | $13.23 |
| 2017 | $2.80 | $32.47 | $0.44 | $0.00 | $12.46 |
| 2018 | $1.44 | $26.01 | $0.79 | $0.24 | $0.00 |
| 2019 | $1.02 | $27.77 | $0.28 | $0.00 | $16.65 |
| 2020 | $1.72 | $28.42 | $0.44 | $0.00 | $9.72 |
| 2021 | $1.09 | $64.64 | $0.00 | $0.00 | $0.00 |
| 2022 | $2.57 | $29.53 | $0.00 | $0.00 | $17.36 |
| 2023 | $2.25 | $29.75 | $0.09 | $0.00 | $15.96 |
| 2024 | $1.73 | $4,942.88 | $0.17 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Geron Corporation's (GERN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $4,942.88
- Current price
- $1.58
- AI upside
- +312,740.51%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.77
-51.27% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| GERN | Geron Corporation | $1.58 | 1.07B | +312,741% | -51% | — | — | -6.40 | 3.99 | 14.52 | -5.38 | — | 3.99 | 98.37% | -225.64% | -226.73% | -66.09% | 7931.16% | -35.34% | 0.43 | -9.39 | 5.56 | 5.04 | -0.28 | -1562.00% | 3238692.00% | 3009.00% | -19.62% | -2.48 | 10011.32% | 0.00% | 0.00% | 0.00% | -4.79 | -3.80 | 10.82 | -2.06 |
| ARVN | Arvinas, Inc. | $13.27 | 974.25M | +82% | -40% | -97% | — | -10.76 | 2.00 | 3.31 | -2.55 | — | 2.00 | 98.02% | -43.75% | -30.77% | -16.23% | 32.32% | -8.93% | 0.02 | — | 4.92 | 4.88 | 1.78 | -5379.00% | -30.00% | 559.00% | -31.73% | -1.92 | 77.55% | 0.00% | 0.00% | 15.59% | -1.67 | -0.70 | 0.73 | -0.54 |
| AVBP | ArriVent BioPharma, Inc. … | $22.97 | 948.23M | — | — | — | — | -8.55 | 2.67 | — | -5.83 | -47.58 | 2.67 | 0.00% | — | — | -39.36% | -469.29% | -36.75% | 0.00 | — | 13.14 | 12.70 | 0.92 | 1797.00% | — | 2573.00% | -10.20% | -4.06 | -349.38% | 0.00% | 0.00% | 0.00% | -4.98 | -6.69 | — | 22.46 |
| DAWN | Day One Biopharmaceutical… | $10.60 | 1.09B | +166% | +52,842% | — | — | -9.99 | 2.43 | 6.78 | -5.99 | -509.45 | 2.53 | 89.12% | -80.76% | -67.85% | -22.74% | 1066.44% | -19.68% | 0.01 | — | 8.02 | 7.73 | 1.84 | 196.00% | 2060.00% | 2964.00% | -9.71% | -1.71 | 884.82% | 0.00% | 0.00% | 6.71% | -4.96 | -6.09 | 4.01 | 8.31 |
| LENZ | LENZ Therapeutics, Inc. | $13.49 | 422.1M | — | — | — | — | -10.13 | 2.47 | — | -5.96 | — | 2.47 | 0.00% | — | — | -89.37% | 72.47% | -34.84% | 0.01 | — | 20.36 | 20.09 | 0.38 | -8471.00% | — | -91.00% | -11.88% | -5.71 | 74.02% | 0.00% | 0.00% | 0.00% | -5.06 | -4.95 | — | 26.23 |
| REPL | Replimune Group, Inc. | $7.65 | 631.68M | — | — | — | — | -3.38 | 2.01 | — | -1.69 | — | 2.01 | 0.00% | — | — | -62.58% | -1380.14% | -47.60% | 0.18 | -33.15 | 7.95 | 7.82 | 0.14 | -525.00% | — | 409.00% | -23.79% | -3.08 | -1049.44% | 0.00% | 0.00% | 4.35% | -1.64 | -2.15 | — | 0.67 |
| RZLT | Rezolute, Inc. | $3.21 | 307.19M | — | — | — | — | -8.17 | 3.75 | — | -5.53 | — | 3.75 | 0.00% | — | — | -52.56% | 2059.39% | -48.28% | 0.01 | — | 14.37 | 14.09 | 1.16 | -2632.00% | — | 2041.00% | -11.36% | -5.80 | 1780.51% | 0.00% | 0.00% | 4.00% | -5.53 | -6.40 | — | 23.66 |
| SVRA | Savara Inc. | $6.02 | 1.22B | — | — | — | — | -5.37 | 3.01 | — | -3.38 | -11.82 | 3.20 | 0.00% | — | — | -61.50% | -3224.37% | -49.11% | 0.16 | — | 13.73 | 13.40 | -0.11 | 4545.00% | — | 7352.00% | -17.29% | -6.05 | -2784.35% | 0.00% | 0.00% | 0.19% | -3.35 | -3.88 | — | 3.70 |
| TYRA | Tyra Biosciences, Inc. | $33.31 | 1.78B | — | — | — | — | -7.24 | 1.82 | — | -2.80 | — | 1.82 | 0.00% | — | — | -31.60% | -1368.86% | -29.34% | 0.02 | — | 23.81 | 23.53 | 0.83 | -679.00% | — | 3836.00% | -11.25% | -4.78 | -925.54% | 0.00% | 0.00% | 5.54% | -2.79 | -4.13 | — | 17.59 |
| VALN | Valneva SE | $11.09 | 954.23M | +215% | -66% | -82% | — | -34.66 | 2.34 | 2.50 | 14.73 | — | 2.72 | 41.89% | 7.86% | -7.22% | -7.91% | 6.06% | -2.55% | 1.19 | 0.56 | 2.61 | 1.78 | 1.50 | -8836.00% | 1032.00% | -6146.00% | -19.71% | -0.59 | -38.00% | 0.00% | 0.00% | 8.17% | 35.45 | -5.65 | 2.79 | 0.09 |
| VIR | Vir Biotechnology, Inc. | $9.09 | 1.26B | +144% | -52% | — | — | -2.95 | 1.69 | 18.87 | -2.39 | — | 1.75 | 82.92% | -682.68% | -638.87% | -45.73% | -112.47% | -36.47% | 0.24 | — | 5.54 | 5.03 | 0.11 | -1749.00% | -761.00% | -1257.00% | -30.66% | -4.22 | -95.31% | 0.00% | 0.00% | 0.00% | -2.17 | -2.57 | 14.85 | 0.63 |
About Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
- CEO
- Harout Semerjian
- Employees
- 229
- Beta
- 0.62
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.77 ÷ $1.58) − 1 = -51.27% (DCF, example).